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Women with evidence of high intake ratios of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) relative to the omega-6 arachidonic acid have been found to have a reduced risk of
breast cancer compared with those with low ratios in some but not all case–control and cohort studies. If increasing
EPA and DHA relative to arachidonic acid is effective in reducing breast cancer risk, likely mechanisms include
reduction in proinflammatory lipid derivatives, inhibition of nuclear factor-κB-induced cytokine production, and
decreased growth factor receptor signaling as a result of alteration in membrane lipid rafts. Primary prevention
trials with either risk biomarkers or cancer incidence as endpoints are underway but final results of these trials
are currently unavailable. EPA and DHA supplementation is also being explored in an effort to help prevent or
alleviate common problems after a breast cancer diagnosis, including cardiac and cognitive dysfunction and
chemotherapy-induced peripheral neuropathy. The insulin-sensitizing and anabolic properties of EPA and
DHA also suggest supplementation studies to determine whether these omega-3 fatty acids might reduce
chemotherapy-associated loss of muscle mass and weight gain. We will briefly review relevant omega-3 fatty acid
metabolism, and early investigations in breast cancer prevention and survivorship.Introduction
Although the predominant driving force in breast car-
cinogenesis has been thought to be hormonal, cytokine
production and inflammation are also being recognized
as important in breast cancer development and progres-
sion [1,2]. A progressive increase in activated macro-
phages and T cells is observed between normal breast
tissue, proliferative breast disease, and breast cancer
[3,4]. The stimulus for the increase in inflammatory cell
infiltration observed with proliferative breast disease and
breast cancer is unknown but probably has varying
etiologies including immunogenic gene alterations in
epithelial cells [5], reaction to breakdown of basement
membrane components [4], and for obese women excess
cytokine production from dysfunctional adipocytes [6].
The long-chain omega-3 fatty acids eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) are import-
ant in generating bioactive lipid mediators important in
inflammation resolution [7]. As key components of
phospholipid membranes and lipid rafts that serve to* Correspondence: cfabian@kumc.edu
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unless otherwise stated.organize or separate molecules, these fatty acids also
affect cell signaling thought to impact breast carcino-
genesis [8-12]. The ability of long-chain omega-6 fatty
acids to modulate inflammation and other physiologic
processes is dependent on concomitant levels of the
proinflammatory omega-6 arachidonic acid (AA) as
well as an individual’s genetic makeup governing lipid
metabolism [13-16].
Interest in the use of supplementary omega-3 fatty
acids to reduce risk of cancer and other chronic debili-
tating conditions, including cardiovascular disease and
cognitive impairment, stems from several longstanding
avenues of investigation: 1) an increased incidence of
breast cancer and heart disease in western societies with
low omega-3:omega-6 fatty acid intake ratios; 2) a very
low incidence of these two conditions in populations
with high marine omega-3 fatty acid intake (Japan and
natives of Alaska and Greenland); 3) a dramatic increase
in the incidence of breast cancer and cardiovascular
disease in cohorts from low-incidence populations who
migrate to western countries and/or adopt a western diet
[15,17]; and 4) the demonstrated importance of adequate
DHA in retinal and brain development and cognitive
function [18,19].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has not been defined, a ratio approaching 1:1 or 1:2
similar to that of precivilized man is generally accepted
as associated with a low incidence of diseases character-
ized by chronic inflammation, and therefore is desirable
[16,20]. By the early 1900s the omega 3:omega-6 intake
ratio in the United States was estimated at 1:5, probably
due to the high dietary content of corn oil products and
corn-fed animals. Today, largely due to the >1,000-fold
increase in use of soybean oil in the last several decades,
the dietary omega 3:omega-6 intake ratio is now 1:10 or
lower [16,21]. Although much of the imbalance is prob-
ably due to the increase in omega-6 consumption, it has
been suggested that the most practical remedy may actu-
ally be to increase long-chain or marine omega-3 intake
rather than to attempt to markedly reduce omega-6
intake [22,23].
We will briefly review omega-3 and omega-6 fatty acid
metabolism and function, preclinical mechanistic and
prevention studies, as well as selected case–control and
prospective cohort studies, and ongoing trials relevant to
breast cancer prevention. Reports dealing with omega-3
fatty acids and breast cancer recurrence as well as otherLinoleic Acid
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anti-inflammatory products respectively.relevant survivorship topics including insulin resistance
and obesity, cardiovascular disease and cognition will
also be discussed.
What are omega-3 and omega-6 fatty acids and
how do they work?
Omega-3 and omega-6 fatty acids are a group of essen-
tial polyunsaturated fatty acids (PUFAs) that play im-
portant roles in cell membrane structure, fluidity, and
cell signaling [13]. The designation 3 or 6 is structural,
referring to the double bond on the third or sixth carbon
respectively from the methyl group [13]. The most abun-
dant dietary PUFAs are the short-chain omega-3 alpha
linolenic acid (ALA) and the omega-6 linoleic acid (LA),
most often ingested as plant oils. The longer chain
omega-3 PUFAs EPA and DHA, commonly referred to
as marine fatty acids, are most efficiently obtained from
fatty cold water fish such as salmon, whereas the long-
chain omega-6 fatty acid AA is obtained most efficiently
from eggs, poultry, and meat [24-26] (see Figure 1). Un-
less EPA, DHA, and AA are directly ingested, they must
be derived from ALA and LA, respectively. In general,
the desaturases and elongases have a greater affinity forα–Linolenic Acid 
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take of LA, generally more AA than EPA and DHA is
formed [24].
Whether ingested or synthesized, PUFAs are either ox-
idized for fuel, stored in triacylglycerol, taken up in
phospholipid membranes for eventual use as substrates
by cyclooxygenase (COX) and lipoxygenase (LOX) en-
zymes, or used as ligands for G receptors [26]. Neither
LA nor ALA is readily converted to bioactive lipid prod-
ucts due to low uptake into phospholipid membranes.
However, 5 to 10% of both LA and ALA can be con-
verted to the longer chain PUFAs that are readily taken
up in phospholipid membranes and form the substrates
for conversion to bioactive lipid products by COX and
LOX enzymes [26] (see Figure 2).
The omega-6 PUFA AA and its derivatives are import-
ant in a diverse set of physiologic functions including
initiation and sustainment of inflammation (for example,
T-cell and monocyte activation, chemotaxis), platelet
aggregation, endothelial adhesion molecules, ovulation,
parturition, and muscle strength. The omega-3 fatty
acids EPA and DHA and their derivatives are important
for retina and brain development, cognitive function, and
in the production of minimally inflammatory eicosanoidsD
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Figure 2 Metabolic pathways for omega-6 and omega-3 fatty acids that re
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and various tissue protectins [20,22]. Although most of
the bioactive lipid mediators of interest are a result of
COX and LOX enzyme activity on the long-chain PUFAs
EPA, DHA, and AA, 15-LOX acts on the short chain LA
to form 13(S)-hydroxyoctadecadienoic acid, which is prob-
ably carcinogenic and is known to increase mammary
tumor proliferation [22] (see Figure 2). EPA and DHA
compete with AA as substrates for COX and LOX en-
zymes although EPA is a poorer substrate than AA, at
least for COX [24].
Upon inflammatory stimulus, the enzyme phospholip-
ase A2 releases AA from phospholipid membranes of
monocytes and predominantly proinflammatory deriva-
tives are produced (Figure 2). COX-1 and COX-2 en-
zymes are responsible for AA-derived prostaglandin E2
and other series-two prostaglandins and thromboxanes
[15,24]. 5-LOX, 12-LOX, and 15-LOX are responsible
for generation of the series-four leukotrienes and lipox-
ins. Leukotrienes have chemotactic and other effects on
inflammatory cells.
In general, the action of COX and LOX enzymes on
the omega-3 fatty acids EPA and DHA is to produce
eicosanoids with less affinity for the correspondingHA
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cell recruitment and promote phagocytosis. The net ef-
fect if EPA and DHA are present in sufficient amounts
relative to AA is anti-inflammatory or inflammation re-
solving. The action of COX on EPA gives rise to the
series-three prostaglandins and thromboxanes, whereas
actions of 5-LOX and 15-LOX ultimately produce the
series-five leukotrienes and resolvins. LOX enzymes
are also responsible for the DHA-derived resolvins
and eventual production of neuroprotectins [15,26]
(see Figure 2).
Recommended and average intakes and sources
of omega-3 and omega-6 fatty acids
No dietary reference intake has been established for EPA
and DHA. Although the dietary reference intake for
omega-3 ALA of 1.1 g/day for women [27] is achieved
by the average intake in the United States of 1.3 g/day,
this is only about 1/10 of the 13 to 15 g daily intake of
omega-6 LA [28].
Given the general health benefits increasingly recog-
nized for EPA and DHA, many organizations have made
recommendations for direct intake of 200 to 500 mg/day
EPA +DHA for adult general health in the form of fish
or fish oil, krill oil, or algae oil supplements (see Table 1).
Average intakes of EPA and DHA combined, usually
from fish or supplements, is ~100 mg/day or 0.1 to 0.2%
of calories. Intake of AA is ~250 mg/day, generally from
eggs, meat, and poultry [21,25,28].
The omega-3 fatty acid intakes recommended for
healthy individuals are not likely to be effective inTable 1 Recommended intakes of EPA + DHA by cohort and o
Cohort Source
General health
Adults US Department of Agriculture
Adults European Food Safety Agency
Adults World Health Organization:
Adults Academy of Nutrition and Dietetics
Adults without CHD American Heart Association
Adults International Society for the Study of
Pregnancy
Pregnant/lactating International Society for the Study of
Pregnant/lactating European Food Safety Agency
Heart disease and inflammatory disorders
CHD American Heart Association
Patients with high TG American Heart Association
Generally viewed as safe upper limit
Population US Food and Drug Administration
Population European Safety Authority
CHD, coronary heart disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acchronic inflammatory conditions, given the level of
omega-6 fatty acids in our diets [15,23,25,28]. If the ratio
of EPA +DHA to AA in blood or tissue is the key factor
[25,28], an intake of ~2 to 3 g/day combined EPA and
DHA, or at least 2% of calories, is likely to be needed to
result in a tissue level ratio of EPA +DHA to AA that
approaches or exceeds unity. Doses generally exceeding
2 g/day combined EPA +DHA are needed to reduce
prostaglandin E2 levels [26] and doses of 3 to 3.5 g/day
combined EPA +DHA are most often used in the treat-
ment of hypertriglyceridemia or inflammatory disorders
such as rheumatoid arthritis [15,29]. No tolerable upper
limit has been set for EPA and DHA, although the US
Food and Drug Administration recognizes doses of up
to 3 g/day as safe and the European Safety Union up to
5 g/day as safe [30]. Side effects of fish oil supplements
or EPA +DHA ethyl esters include fishy burps, dyspep-
sia, gas, and diarrhea [15,29].
Primary sources of EPA and DHA are fish and supple-
ments, which vary dramatically in their content. DHA is
generally present in equal or higher amounts than EPA
in seafood but the total amount of EPA and DHA as well
as the ratios of EPA to DHA vary by supplement, and in
many over-the-counter supplements EPA may be almost
twice as high as DHA (see Tables 2 and 3). Fatty cold
water fish such as salmon, herring, and mackerel have
the highest levels of DHA and EPA, with lower levels in
shellfish and many popular freshwater fish. A total of
2.4 g EPA +DHA can be obtained from a 4 oz (114 g)
serving of wild Atlantic salmon but one would have to
eat 8 oz (227 g) canned pink salmon, 1 lb (0.45 kg)rganization
Daily recommendation
≥250 mg
≥250 mg
≥250 mg
≥500 mg
∼500 mg (fatty fish≥ 2 times/week)
Fatty Acids and Lipids ≥500 mg
Fatty Acids and Lipids ≥500 mg (≥300 mg DHA)
≥250 mg (100 to 200 mg DHA)
∼1 g
2 to 4 g
≤3 g EPA + DHA
5 g EPA + DHA
id; TG, triglyceride.
Table 2 Dietary sources of EPA + DHA
EPA + DHA (mg) Source (4 oz or 114 g serving)
2,400 Salmon (Atlantic), herring (Pacific)
2,290 Herring (Atlantic)
2,060 Mackerel (Pacific and jack)
1,940 Salmon (chinook)
1,830 Whitefish
1,710 Tuna (bluefin)
1,560 Oysters (cooked)
1,490 Salmon (coho, farmed)
1,370 Mackerel (Atlantic), trout (farmed, rainbow)
1,190 Pink salmon canned
1,110 Bass (striped)
1,030 Trout (mixed species)
980 Tuna albacore canned
870 Bass (sea bass, freshwater)
540 Halibut (Atlantic and Pacific)
470 King crab
340 Flounder/sole
320 Tuna (yellowfin), Cod (Pacific)
270 Catfish wild
220 Lobster
180 Cod (Atlantic)
150 Tilapia
120 Shrimp
100 Catfish (farm)
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.
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amount (see Table 2) [31].
How might EPA and DHA act to prevent breast
cancer? Preclinical mechanistic studies
Most of the work assessing how EPA and DHA might
work to reduce breast cancer risk has been performed in
in vitro or in transgenic mouse models and is far from
conclusive. However, the predominant mechanisms are
thought to be: a reduction in proinflammatory eicosa-
noids and an increase in inflammation-resolving deriva-
tives as detailed previously (Figure 2); a reduction
in oncogenic protein signaling through disruption of
plasma membrane lipid rafts; a reduction in cytokine
production; and an increase in apoptosis following acti-
vation of plasma membrane GRP120 protein receptor,
which along with activation of peroxisome proliferator-
activated receptor gamma blocks nuclear factor-κB
translocation to the nucleus [8,9].
EPA and DHA disrupt lipid rafts, sphingolipid/
cholesterol-enriched microdomains of plasma membranesthat optimize signaling by concentrating proteins. Lipid
rafts are particularly important for several tyrosine kinase
receptors, and reduction in epidermal growth factor recep-
tor and human epidermal growth factor-2 receptor level
and activation has been demonstrated in transformed and
malignant cells [10-12]. A decrease in epidermal growth
factor receptor and human epidermal growth factor-2 sig-
naling would be expected to reduce proliferation, and a de-
crease in Ki-67 has indeed been observed in benign and
malignant mammary tissue after EPA and DHA supple-
mentation in most preclinical models [32-35].
Nuclear factor-κB nuclear translocation and signaling
is reduced via the agonist effects of EPA and DHA on
peroxisome proliferator-activated receptor gamma as
well as interaction with the G protein receptor GPR120,
with expected reduction in inhibitors of apoptosis as
well as cytokines, adhesion molecules, and metallo-
proteases [9]. Additional preclinical studies suggest
that EPA and DHA increase expression of BRCA1/2,
phosphatase and tensin homolog (PTEN), and other
proteins associated with cell cycle control and DNA
repair [32,36,37].
Preclinical models of mammary cancer prevention
Studies in rodent models find that increasing the ratio of
total omega-3:omega-6 in feed to >1 (usually with
EPA + DHA between 8 and 25% of calories) reduces
mammary cancer incidence and multiplicity by 20 to
35% [22,32,37-41]. Reductions in tumor incidence
have been observed in the estrogen receptor-negative
MMTV-HER-2/neu transgenic mice [39,40], the es-
trogen receptor-positive NMU rat model [32,37], and the
estrogen receptor-positive DMBA rat model [41-43]. The
minimum dose of marine omega-3 fatty acids for effect is
not clear and may vary by animal model, source of EPA
and DHA (fish oil versus ethyl esters), and total amount
and type of fat in the diet. Other important experimental
conditions include when in an animal’s lifespan supple-
mentation is started (younger may be more protective
than older), and whether agent is added to feed or ad-
ministered by gavage as omega-3 fatty acids are readily
oxidized once exposed to light [38]. Several preclinical
studies suggest that EPA/DHA supplementation may
be most optimal for prevention of estrogen receptor-
positive breast cancer when used with another che-
moprevention agent such as vitamin D [41], a selective
estrogen receptor modulator [43], or celecoxib [42].
Human studies
Results of case–control and cohort studies have to date
been variable, probably reflecting the heterogeneity of
cohorts, methods used to assess omega-3 and omega-6
exposure, time from exposure when measures were
taken, dose, and response endpoint.
Table 3 Amounts of EPA and DHA in commonly available supplements
Brand/product EPA (mg) DHA (mg) Comment
Cardiotabs omega-3 enteric-coated 270 705
Cardiotabs omega-3 extra strength + vitamin D3 400 800
Cardiotabs ultra strength liquid omega-3 + vitamin D3 (per 5 ml) 610 1570
DSM MEG-3® ethyl ester 1,000 mg capsules 420 210 As ethyl esters
GlaxoSmithKline Lovaza™ 445 385 As ethyl esters
GNC ultra triple strength omega 1560 EPA & DHA 719 281
GNC Now® ultra omega-3 500 250
GNC Natrol® omega-3 fish oil 1,200 mg 216 144
GNC Triple Strength Omega Complex 647 253
GNC Triple Strength Fish Oil 1500 540 360
Kirkland Signature™ omega-3 fish oil 410 274 As ethyl esters
NatureMade Fish Oil 1,200 mg 180 120
NatureMade Ultra Omega-3 Fish Oil 1,400 mg 683 252
Nordic Naturals Ultimate Omega D3, 1,000 mg, soft gels, lemon 650 450
Puritan’s Pride Triple Omega 3-6-9 fish and flax oils 398 to 450 255 to 300
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.
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Omega-3 and omega 6 fatty acids are incorporated at
different rates in different tissues and tissue components.
Levels as a percentage of total fatty acids vary tremen-
dously between tissues/organs although, with supple-
mentation, levels of EPA and DHA rise in a fairly
proportional manner [44]. Substantial increases in
monocyte membrane DHA and EPA and decreases in
monocyte AA may be seen as early as 1 week after be-
ginning supplementation and do not change dramatically
over the ensuing several weeks [9,26]. The time to EPA
maximum uptake is ~2 weeks in plasma triglycerides,
3 weeks in serum cholesterol esters, ~2 months in red
blood cells (RBCs), and >12 months for most types of
adipose tissue. The highest levels of EPA and DHA in
the blood are generally in the RBC membranes (RBC
phospholipids), plasma phospholipids, and cholesterol
esters and platelets, although mononuclear cells also
contain appreciable amounts [45]. The concentration of
EPA and DHA in subcutaneous or breast adipose is 1/10
or less of that in the blood compartments [44]. DHA is
generally much higher than EPA in most body organs,
including the brain and retina, but its incorporation into
RBCs lags behind EPA [26,28,29,46]. Women generally
have higher levels of EPA and DHA than men following
equivalent dosing, and older women have higher levels
than younger women [45]. Individuals who take fish oil
supplements tend to take them daily whereas consump-
tion of fish may be more intermittent. Browning and
colleagues determined in a 12-month study of adults
taking identical weekly doses of EPA +DHA that those
taking continuous daily doses had higher EPA and DHAlevels in monocytes and platelets than those taking inter-
mittent doses [47].
For clinical trials, chronic exposure is generally
assessed by measuring EPA, DHA, and AA RBC phos-
pholipids, although some investigators feel that mono-
cyte or platelet phospholipid measures are superior to
those in RBCs [29].
Case–control studies
Results of case–control studies, particularly when ques-
tionnaires are used as the primary measure of exposure,
are mixed, probably reflective of the accuracy of recall
and food frequency questionnaires in estimating dietary
intake. There is no significant association between total
fish intake and breast cancer particularly in populations
where total fish and fatty fish consumption tends to be
low [48,49]. EPA and DHA content varies tremendously
by type of fish, which may not be well specified in the
questionnaires. However, two case–control studies (one
from Mexico and another from the United States) using
dietary recall instruments suggest breast cancer risk re-
duction in premenopausal women with higher intakes of
omega-3 fatty acids from diet and supplements [50,51].
Measurement of the fatty acid composition in blood
cell membranes (phospholipids) and adipose is thought
to be a good indicator of chronic exposure to omega-3
and omega-6 fatty acids and thus avoids some of the
problems with dietary recall. A nested case–control
study within a prospective cohort of women in Shanghai
China, a population with relatively high fish intake,
found that total omega-3 fatty acids and EPA in red cells
were associated with significantly lower risk of proliferative
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were reported in a Japanese cohort where total omega-3,
EPA, and DHA in red cells was inversely associated
with breast cancer risk [54]. Another case–control
study suggested reduced risk of breast cancer with
higher ratios of omega-3 to omega-6 in breast adipose
[55]. No association was reported between the risk
biomarker mammographic breast density and omega-3
fatty acids [56].
Prospective cohort studies of omega-3 fatty acids
and breast cancer risk
A meta-analysis of 16 prospective cohort studies exam-
ining marine omega-3 intake suggests a reduction in
breast cancer risk when individuals with highest intakes
are compared with those with lowest intakes of marine
PUFA (EPA, docosapentaenoic acid, and DHA) in the
diet or the diet plus supplements [57]. The method for
assessment of marine PUFA exposure varied from diet-
ary questionnaire to blood or tissue n-3 PUFA assess-
ment. Overall the relative risk for highest exposure was
0.86 (95% confidence interval, 0.97 to 1.03). The affect
appeared strongest for marine PUFA in postmenopausal
women but there were fewer premenopausal women
studied [57]. In three of the largest studies – the
Singapore Chinese Health Study [58], the Japanese
Collaborative Cohort Study [59], and the Vitamins and
Lifestyle (VITAL) study from western Washington state
[60] – there was a significant reduction in relative risk in
the individual trials ranging from 31 to 50%. Current use
of fish oil supplements (generally 300 mg EPA + DHA
or more per capsule) in the VITAL trial in women
aged >50 years was associated with a 32% reduction
in risk of breast cancer (hazard ratio, 0.68; 95% confi-
dence interval, 0.50 to 0.92) [60,61].
Eight studies were available for dose–response ana-
lysis, which showed that a 0.1 g/day increment and/or
0.1% of energy intake increments were associated
with a 5% reduction in breast cancer risk [57]. In
this same meta-analysis no association was observed
between total fish intake, total PUFA or ALA (the
shorter chain omega-3 fatty acid) intake and breast
cancer risk [57].
A recent meta-analysis combined six prospective
nested case–control studies and five cohort studies in
which the omega-3:omega-6 intake ratio and/or omega-
3:omega-6 ratio in serum phospholipids was known. There
were over 274,000 women, and more than 8,300 breast
cancer events. Their conclusions were that each 1/10 in-
crement in the dietary n-3:n-6 ratio was associated with a
6% reduction in breast cancer risk, and amongst US sub-
jects each 1/10 increment in the serum n-3:n-6 phospho-
lipid ratio was associated with a 27% reduction in breast
cancer risk [49].Interventional studies for primary prevention of
breast cancer
Although one is not likely to achieve EPA +DHA intake
in human trials at the same percentage of calories as in
animal prevention trials, doses of EPA and DHA ethyl
esters up to ~7 g/day given to healthy women are well
tolerated [62]. A dose of 3.4 g/day DHA + EPA ethyl
esters, providing ~ 2% of calories, is US Food and Drug
Administration approved for treatment of hypertriglyc-
eridemia. Importantly, this dose should produce an
EPA + DHA:AA ratio approaching equivalence and
thus provide an anti-inflammatory effect.
Human studies in healthy individuals show little effect of
marine PUFA on blood inflammatory biomarkers, although
a recent randomized trial in healthy young adults given 0,
300, 600, 900, or 1,800 mg/day EPA +DHA for 5 months
showed a marginal decrease in serum tumor necrosis fac-
tor alpha (P = 0.08) but no change in interleukin-6 [63].
Human studies in inflammatory disorders show little
evidence of a systemic anti-inflammatory effect such as
reduction of cytokines or prostaglandin E2 levels with
doses of combined EPA +DHA less than ~3.5 g/day
and/or EPA-alone doses <2.7 g/day [26,64]. However,
experts in this area suggest that systemic measures of
cytokines in inflammatory conditions are likely to be
insensitive compared with measuring conditions in the
tissue of interest [65].
Signori and colleagues are conducting a trial of raloxifene
30 mg, raloxifene 60 mg, Lovaza™ (GlaxoSmithKline) 4 g,
Lovaza™ 4 g + raloxifene 30 mg, or no intervention in post-
menopausal women with >25% breast density. No change
with Lovaza™ has been found in the first 46 women in sec-
ondary endpoint blood risk biomarkers such as insulin-like
growth factor I and insulin-like growth factor-binding
protein 3 or the inflammatory marker high-sensitivity
C-reactive protein [66].
We have completed separate pilot studies of 3.4 g/day
EPA +DHA ethyl esters (4 g Lovaza™) administered for
6 months to explore effects on benign breast tissue risk
biomarkers for breast cancer in premenopausal and
postmenopausal women at increased risk for breast
cancer. Favorable modulation of several tissue risk bio-
markers for breast cancer was observed [67,68].
A study of particular interest is the ongoing VITAL
trial (NCT01169259) which aims to randomize over
28,000 men and women to vitamin D3 (2,000 IU/day),
omega-3 fatty acids (840 mg EPA +DHA), both, or none,
with a primary outcome of reduction in risk for cancer,
stroke, and other diseases. Eligible women must be age
55 years and over.
Omega-3 fatty acids and breast cancer survivorship
There is also interest in EPA and DHA for improvement
of outcomes after a diagnosis of breast cancer. Breast
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and obesity, bone density loss, and chemotherapy-
associated cognitive impairment and peripheral neur-
opathy are common concerns during the survivorship
period. Although there is little in the way of definitive
interventional trials, we will review here some of the
more interesting preliminary results.
EPA and DHA and reduction of breast cancer recurrence
Higher intakes of EPA and DHA from dietary sources
were reported to be associated with a 25% reduction in
breast cancer recurrence and improved overall mortality
in a large cohort of over 3,000 women with early stage
breast cancer followed for a median of 7 years [69]. One
reason for this observation may be enhancement of at
least some types of chemotherapeutic cytotoxicity, which
has been reported for concomitant administration of
DHA with anthracyclines [70,71]. This enhanced cyto-
toxicity probably results from alteration in membrane
lipid rafts, which increases surface expression and clus-
tering of the death receptor CD95 in mammary cancer
cell lines treated with EPA and DHA and doxorubicin
[72]. Improved outcome with DHA added to chemother-
apy in a small phase II trial has been reported in meta-
static breast cancer patients [73]. This observation raises
the question of whether cardiac toxicity might also be
increased by adding EPA or DHA to anthracyclines, but
this does not appear to be the case at least in rats [74].
EPA and DHA to reduce cardiac events
Cardiac events are the second most common cause of
mortality in women with breast cancer, and the most
common cause of death for women with stage I breast
cancer over the age of 65. EPA and DHA reduce triglyc-
erides and platelet aggregation and are thought to have
an anti-arrhythmic effect. EPA and DHA supplementa-
tion have been noted to be associated with reduced car-
diac deaths in the general population [75,76]. A highly
purified prescription strength form of ~3.4 g/day EPA
and DHA (Lovaza™, formerly omacor, 4 g/day) is US
Food and Drug Administration approved for treatment
of hypertriglyceridemia and has been shown to reduce
triglycerides and nonhigh-density lipoproteins to a
greater extent than a statin alone in individuals with
mixed dyslipidemia and triglycerides >200 mg/dl [77].
This highly purified prescription formulation has also
been shown to reduce cardiac events and mortality in
individuals with a prior myocardial infarction at lower
doses of 1 g/day [77]. However, a recent secondary pre-
vention trial with 1 g/day EPA and DHA compared with
1 g/day olive oil did not show any cardioprotective effect
[78]. A recent meta-analysis of EPA and DHA in moder-
ate doses also showed no benefit [79]. The cause of
these discrepancies is open to speculation. Possibilitiesinclude the following: 1) a lack of additional benefit
for EPA + DHA in women with cardiac disease already
on optimal medical management; 2) the placebo, often
olive oil, may also have cardiovascular benefit; 3) or
the highly purified forms of EPA + DHA may have spe-
cial properties such as lower reactive oxygen species
than less purified forms of fish oil [80]. Trials such as
the VITAL trial in women without a prior history of
heart disease will be of great interest.
EPA and DHA to reduce bone density loss and arthralgias
Loss of bone density and increased fracture rate are a
side effect of premature menopause caused by cytotoxic
chemotherapy or surgical ovarian ablation in premeno-
pausal women or use of aromatase inhibitors in post-
menopausal women. EPA and DHA probably inhibit
RANK ligand and osteoclast formation [81]. A small
randomized pilot trial suggests that 3 g/day EPA and
DHA inhibits bone reabsorption in individuals taking
aromatase inhibitors [82]. The anti-inflammatory activity
and beneficial effects of EPA and DHA on rheumatoid
arthritis have led to a clinical trial of high-dose EPA and
DHA versus placebo in women who have aromatase
inhibitor-induced arthralgias. This cooperative group
study of 262 women has been reported in abstract form
and no benefit was observed [83]. A small randomized
trial of omega-3 fatty acids to protect against taxane-
induced neuropathy suggests benefit [84] and further
studies are needed.
EPA and DHA to prevent insulin resistance and
sarcopenic weight gain
EPA and DHA help prevent obesity and insulin resist-
ance particularly in animal models fed a high-fat diet
[85,86], but effects in humans have yet to be proven.
Sarcopenic weight gain is common during adjuvant
chemotherapy for breast cancer. The anabolic effects of
EPA and DHA might help reduce muscle mass loss and
weight gain during treatment and weight gain following
diagnosis, but studies in this area have yet to be con-
ducted [87,88]. Results of the Muscle Mass, Omega-3,
Diet, Exercise and Lifestyle (MODEL) trial in healthy in-
dividuals aged >70 years examining the effects of 90 mi-
nutes of exercise weekly, vitamin D3 (2,000 IU/day) or
1 g EPA and DHA daily are awaited with interest [89].
EPA and DHA and cognition
Cognitive abnormalities are observed in 20 to 70% of
women after chemotherapy depending on the agents
used, intensity and duration of treatment, predisposing
factors, and type and scoring of cognitive tests [90,91].
DHA is the most abundant PUFA in the brain and is in-
volved in multiple functions including cell signaling,
neurogenesis, neuroprotection, and learning and memory
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50% reduction in risk of multicause dementia with in-
creased dietary intake of DHA or increased blood levels
of DHA [19]. In meta-analyses, DHA supplementation
improves attention, processing speed and immediate re-
call, learning, and memory in individuals with cognitive
impairment without dementia but not in those with de-
mentia [92,93]. Probable mechanisms include suppression
of oxidative stress [94], decreases in proinflammatory lipid
derivatives from AA, an increase in inflammation resolv-
ing and protective lipid derivatives, enhanced production
of neurotransmitters [95], and reduced production and ac-
cumulation of amyloid B peptide toxin [19]. Doses of
DHA administered as supplements for cognitive improve-
ment are generally in the range of 1,800 mg/day. Studies
utilizing DHA or DHA+ EPA as a neuroprotectant during
chemotherapy are needed.
Conclusion
The inflammation-resolving properties and favorable ef-
fects of EPA and DHA on oncogenic proteins, as well as
on the cardiovascular, bone, and central nervous system,
make them excellent candidates for primary and second-
ary breast cancer prevention trials for individuals at
increased risk as well as breast cancer survivors. Inter-
ventional trials in these cohorts are ongoing.
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